Platelet protease activated receptor 4 (PAR 4) receptor genotype is associated with an increased risk of preterm birth

Abstract

Background: Platelet protease activated receptor-4 (PAR4) Thr120 is a common genetic variant associated with increased platelet activity. Increased platelet activity is implicated in the pathogenesis of preeclampsia and preterm birth.Objective: Compare the rate of preeclampsia and preterm birth in pregnant individuals homozygous for PAR4 Thr120 variant vs not.Study Design: This is a prospective cohort study of patients who delivered November 2020-July 2021. Maternal blood collected on admission for PAR4 genotyping. The primary outcome was the rate of preeclampsia/gestational hypertension in those with Thr/Thr genotype compared with Ala/Thr or Ala/Ala. Secondary outcomes included rates of preterm birth and placental pathology.Results: Three hundred and twenty singletons were included and 52 (16.3%) were PAR4 Thr/Thr. Those PAR4 Thr/Thr were more likely to be Black (67.3% vs 29.5%, p < .001), younger (28 ± 6 vs 31 ± 6, p = .004), and have higher body mass index (35.2 ± 6.8 vs 33.1 ± 7.4, p = .047). There was no difference in preeclampsia/gestational hypertension (19.2% vs 22.8%, p = .705). Those Thr/Thr had a significantly higher rate of preterm birth (15.4% vs 3.7%, adjusted odds ratio [aOR] 4. 04 [1.47-11.10],

MicroRNA‐26a alleviates tubulointerstitial fibrosis in diabetic kidney disease by targeting PAR4

“…We used bioinformatics analysis to screen the target mRNAs of miR‐26a and found that miR‐26a has potential binding sites in the 3′‐UTR of protease‐activated receptor 4 (PAR4). As a subfamily of G‐protein‐coupled receptors, PAR4 has been reported to be involved in the regulation of various diseases, 12 , 13 , 14 , 15 but its contribution to kidney diseases remaining unknown. In the current study, we analysed the expression of miR‐26a in DKD models and further investigated that miR‐26a improves TIF in DKD via silencing PAR4.…”